about
Induction of cancer-specific cytotoxicity towards human prostate and skin cells using quercetin and ultrasoundRaft-dependent endocytosis of autocrine motility factor/phosphoglucose isomerase: a potential drug delivery route for tumor cellsLymphoma and myeloma cell resistance to cytotoxic agents and ionizing radiations is not affected by exposure to anti-IL-6 antibodyPhage display selection for cell-specific ligands: development of a screening procedure suitable for small tumor specimens.Prostate cancer regulatory networksDysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunitiesEnhanced tumour cell nuclear targeting in a tumour progression model.Alternative TrkAIII splicing: a potential regulated tumor-promoting switch and therapeutic target in neuroblastoma.HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors.Advances of cancer therapy by nanotechnology.New approaches to pharmacotherapy of tumors of the nervous system during childhood and adolescence.Nanoparticle-labeled stem cells: a novel therapeutic vehicle.Targeting the PI3K/Akt/mTOR axis by apigenin for cancer prevention.Reduced in vivo lung metastasis of a breast cancer cell line after treatment with Herceptin mAb conjugated to chemotherapeutic drugs.Granulin-epithelin precursor as a therapeutic target for hepatocellular carcinoma.Designed hybrid TPR peptide targeting Hsp90 as a novel anticancer agent.Use of oncolytic viruses for the eradication of drug-resistant cancer cells.Selective killing of hepatocellular carcinoma HepG2 cells by three-dimensional nanographene nanoparticles based on triptycene.
P2860
Q24650438-6576325F-0250-4770-8EC5-7A53BC870248Q28473988-6CB8063D-4756-4B56-82EC-58D5600E89A5Q28750048-E08C546D-7866-4977-A52D-4455CD243F5AQ33214333-1B78E88E-A634-4EF8-A256-21FA81B9922CQ33960568-4B632580-F1F0-4109-92F9-54E1AE19ED10Q34139691-3D21F522-CB5D-4604-B2EF-0BCAD3033ACAQ35127787-315F7080-3CAA-4333-8D94-3BDAC1D516B8Q36429595-2B15B2FC-FCFD-4680-BBAC-DE1ACE2AB656Q37069841-4666C9DC-9580-438E-8686-1F66352FD2FBQ37234202-03C4FB09-47F0-41F3-ABDF-34F9E84FC25DQ37422646-447C487B-C87E-4EE5-B763-A341A8A3E864Q37980117-E3B2153B-B17D-47F9-B3C2-63A1C6DCC5FBQ38070195-0CFBB77E-A27E-4FAD-9A05-7FF5D6687118Q39314472-F76EFDD3-B1CC-439D-8B93-5D4FE9FEF8A8Q39994567-9619BCBB-6B47-445C-AF17-19B5EA507D55Q42588374-97DBDC8C-6343-4842-A488-B216F603DA4FQ43159083-9128CA56-185A-40DD-B4D4-0ED167438113Q46768943-0AFA3CDA-EDD7-442A-8A75-73FB6AFCACBF
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Novel approaches for targeted cancer therapy.
@ast
Novel approaches for targeted cancer therapy.
@en
type
label
Novel approaches for targeted cancer therapy.
@ast
Novel approaches for targeted cancer therapy.
@en
prefLabel
Novel approaches for targeted cancer therapy.
@ast
Novel approaches for targeted cancer therapy.
@en
P356
P1476
Novel approaches for targeted cancer therapy.
@en
P2093
H Uri Saragovi
Veronique Guillemard
P304
P356
10.2174/1568009043332989
P577
2004-06-01T00:00:00Z